Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 15/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16867669 | 0.89 | PDE2A (0.62) | PDE2A | |
| SCHEMBL16867690 | 0.81 | PDE2A (0.69) | PDE2A | |
| SCHEMBL18383466 | 0.79 | PDE2A (0.50) | PDE2A | |
| SCHEMBL403588 | 0.75 | PDE5A (0.53) | PDE2APOLBRNASEH1KDM4EALDH1A1 | |
| SCHEMBL16867689 | 0.75 | PDE2A (1.00) | PDE2A | |
| SCHEMBL19571234 | 0.75 | PDE2A (1.00) | PDE2A | |
| SCHEMBL403796 | 0.75 | PDE5A (0.64) | PDE2APOLBRNASEH1KDM4EALDH1A1 | |
| SCHEMBL16867691 | 0.74 | PDE2A (1.00) | PDE2A | |
| SCHEMBL405407 | 0.74 | POLB (0.57) | PDE2APOLBRNASEH1KDM4EALDH1A1 | |
| SCHEMBL403861 | 0.74 | RNASEH1 (0.51) | PDE2APOLBRNASEH1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087060-B1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-13 | — | — | EP | disclosed |
| US-9815796-B2 | Pyrimidone carboxamide compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815796-B2 | Pyrimidone carboxamide compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-19 | — | — | US | disclosed |
| WO-2015096651-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015633-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE12, PDE3A | PDE2A 1/4885POLB 623/4885RNASEH1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.